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Abstract: The novel COVID-19 pandemic is affecting the world’s population differently: mostly in the
presence of conditions such as aging, diabetes and hypertension the virus triggers a lethal cytokine
storm and patients die from acute respiratory distress syndrome, whereas in many cases the disease
has a mild or even asymptomatic progression. A common denominator in all conditions associated
with COVID-19 appears to be the impaired redox homeostasis responsible for reactive oxygen species
(ROS) accumulation; therefore, levels of glutathione (GSH), the key anti-oxidant guardian in all
tissues, could be critical in extinguishing the exacerbated inflammation that triggers organ failure
in COVID-19. The present review provides a biochemical investigation of the mechanisms leading
to deadly inflammation in severe COVID-19, counterbalanced by GSH. The pathways competing
for GSH are described to illustrate the events concurring to cause a depletion of endogenous GSH
stocks. Drawing on evidence from literature that demonstrates the reduced levels of GSH in the
main conditions clinically associated with severe disease, we highlight the relevance of restoring GSH
levels in the attempt to protect the most vulnerable subjects from severe symptoms of COVID-19.
Finally, we discuss the current data about the feasibility of increasing GSH levels, which could be
used to prevent and subdue the disease.
Keywords: SARS-CoV-2; angiotensin-converting enzyme (ACE); angiotensin-converting enzyme 2
(ACE2); glutathione; inflammation; ROS; N-acetylcysteine; glycine; chloroquine; paracetamol
1. Introduction
Lung inflammation is the main cause of life-threatening respiratory disorders at the severe stage
of SARS-CoV-2 infection, characterized by the so-called “cytokine release syndrome (CRS)”.
The key to fighting this harmful inflammatory response resides in: (i) addressing the mechanism
of the virus penetration into the cell, mediated by binding to and inactivation of the ACE2 protein;
(ii) contrasting the exacerbation of the inflammatory response. The standard pharmacological approach
would suggest either the use of an antiviral drug with the aim of blocking viral replication or the
exploitation of drugs previously validated as inhibitors of some inflammatory pathway in other
chronic diseases. Unfortunately, these drugs are ineffective in healing the most severe cases of
SARS-CoV-2, and additionally, they have several side effects. The baffling aspect of this disease is
the great heterogeneity of response among patients, ranging from severe symptoms to asymptomatic
progression. Understanding the protective mechanisms and the reasons of their failure could provide
a breakthrough in the quest for a cure.
The inflammatory response can be traced back to the pathway of viral entry through its
receptor ACE2. Angiotensin-converting enzyme 2 (ACE2) is a protease that, with its companion
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the angiotensin-converting enzyme ACE, takes part in the renin-angiotensin system (RAS). They are
localized at the cell surface and compete for the same substrates, angiotensin I and II. ACE2 counters
the activity of ACE by reducing the amount of angiotensin-II (ANGII) and increasing ang (1-7) peptide.
The downstream effects of the two enzymes are opposite: ACE activity leads to vasoconstriction,
oxidative stress, inflammation and apoptosis, whereas ACE2 causes vasodilatation, angiogenesis and
anti-inflammatory, anti-oxidative and anti-apoptotic effects [1]. The oxidative stress generated by
ACE activity is due to the effects of its product, ANGII, which increases the production of reactive
oxygen species (ROS) through the activation of NADPH oxidase and the generation of peroxynitrite
anions. In contrast, the ang (1-7) peptide synthesized by ACE2 activity leads to a downregulation of
pro-oxidant pathways, which prevents or attenuates the cellular damage induced by oxidative stress.
Each person has a different balance between ACE and ACE2 and can be more prone to inflammation
if ACE prevails. When this happens, and additionally infection by SARS-CoV-2 downregulates ACE2
abundance on cell surfaces, as suggested by evidence from related coronaviruses [2], the result is the
toxic overaccumulation of ANGII, exacerbated inflammation and, finally, acute respiratory distress
syndrome and fulminant myocarditis (Figure 1). A different balance of ACE/ACE2 can explain the
heterogeneous responses to infection caused by the same virus. The link between the dysregulation
of the RAS cascade and the likelihood or severity of SARS-CoV-2 infection has been discussed in
some recent works [3,4], and it is a matter of importance when the effects of the RAS inhibitors are
debated [5].Antioxidants 2020, 9, x FOR PEER REVIEW 3 of 16 
 
Figure 1. A comprehensive scheme of the interactions between the molecules involved in the renin-
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epithelial cells, such as enterocytes, γ-glutamyl transferase (γ-GT) and dipeptidase (DP), the 
hydrolysis of extracellular GSH is catalyzed to its constituent amino acids, glutamate, cysteine and 
glycine. The three amino acids are adsorbed by transporters. Additionally, intestinal epithelial cells 
can import intact GSH from the lumen via specific plasma membrane transporters. 
Cytosolic synthesis of GSH takes place in two ATP-dependent reactions catalyzed by glutamate-
cysteine ligase (GCL) and glutathione synthase (GS). The activity of these enzymes is regulated by 
many pathways, suggesting that the synthesis of GSH must respond to a multitude of environmental 
conditions. TGFβ1 is one of the major repressors of GCL expression leading to lower levels of GSH 
[9]; because the cytokine activity is induced by ROS and leads to fibrosis [10,11], this implies that in 
a pro-fibrogenic environment, the depletion of GSH occurs through multiple mechanisms, either by 
oxidation or by decreased synthesis [12]. In addition, hypoxia represents an inhibitory signal for GSH 
synthesis, since it decreases the activity of the two key biosynthetic enzymes GCL and GS [13]. On 
the other hand, vitamin D induces the expression of GCL and glutathione reductase genes [14], thus 
increasing the levels of GSH. The GLC gene is induced also by exposure to reactive oxygen species 
and nitric oxide species [15]. 
Glutathione exists in reduced (GSH) and oxidized (GSSG) states. In the reduced state, the thiol 
group of cysteine is able to donate a reducing equivalent (H+ + e−) to other unstable molecules, such 
as ROS. In donating an electron, glutathione itself becomes reactive, but readily reacts with another 
reactive glutathione to form glutathione disulfide (GSSG). Such a reaction is possible due to the 
relatively high concentration of glutathione in cells (up to 5 mM in the liver). The regeneration of 
GSH from GSSG is catalyzed by glutathione reductase (GR) in the GSH redox cycle. GSSG reduction 
occurs at the expense of NADPH, produced by the pentose phosphate pathway (PPP) from glucose 
Figure 1. A compreh nsive scheme of the interactions bet ee lec les involved in the
renin-angiotensin system (RAS) from [3], copyright 2020 by Gang Niu. Reprinted with permi sion.
Reducing the oxidative stress secondary to the imbalance between ACE and ACE2 could be the
best approach for the prevention and treatment of COVID-19. Oxidative stress constitutes a failure of
anti-oxidation defense systems to keep ROS and reactive nitrogen species in check. ROS are signaling
molecules that induce the release of pro-inflammatory cytokines [6], and the dysregulation of this
response plays an essential role in the development of inflammation [7].
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Glutathione (GSH) has the function of “master antioxidant” in all tissues; the high concentration
of the reduced form (millimolar) highlights its central role in the control of many processes such as
detoxification, protein folding, antiviral defense and immune response [8].
The aim of this review is to provide a brief overview of the protective action of GSH against
the exacerbated inflammation triggered by COVID-19 upon ACE/ACE2 imbalance. Furthermore,
we discuss the evidence of the low levels of GSH found in the conditions associated with the severe
outcome of the disease, with the intension of looking into the relevance of restoring GSH levels in the
attempt to protect the most vulnerable subjects from COVID-19.
2. Cellular GSH Homeostasis
Glutathione, a tripeptide composed of glutamate, cysteine and glycine, is an antioxidant molecule
ubiquitous in most living organisms. Intracellular GSH balance is maintained by de novo synthesis,
regeneration from the oxidized form, GSSG, and extracellular GSH uptake. In transporting epithelial
cells, such as enterocytes, γ-glutamyl transferase (γ-GT) and dipeptidase (DP), the hydrolysis of
extracellular GSH is catalyzed to its constituent amino acids, glutamate, cysteine and glycine. The three
amino acids are adsorbed by transporters. Additionally, intestinal epithelial cells can import intact
GSH from the lumen via specific plasma membrane transporters.
Cytosolic synthesis of GSH takes place in two ATP-dependent reactions catalyzed by
glutamate-cysteine ligase (GCL) and glutathione synthase (GS). The activity of these enzymes is
regulated by many pathways, suggesting that the synthesis of GSH must respond to a multitude
of environmental conditions. TGFβ1 is one of the major repressors of GCL expression leading to
lower levels of GSH [9]; because the cytokine activity is induced by ROS and leads to fibrosis [10,11],
this implies that in a pro-fibrogenic environment, the depletion of GSH occurs through multiple
mechanisms, either by oxidation or by decreased synthesis [12]. In addition, hypoxia represents an
inhibitory signal for GSH synthesis, since it decreases the activity of the two key biosynthetic enzymes
GCL and GS [13]. On the other hand, vitamin D induces the expression of GCL and glutathione
reductase genes [14], thus increasing the levels of GSH. The GLC gene is induced also by exposure to
reactive oxygen species and nitric oxide species [15].
Glutathione exists in reduced (GSH) and oxidized (GSSG) states. In the reduced state, the thiol
group of cysteine is able to donate a reducing equivalent (H+ + e−) to other unstable molecules, such
as ROS. In donating an electron, glutathione itself becomes reactive, but readily reacts with another
reactive glutathione to form glutathione disulfide (GSSG). Such a reaction is possible due to the
relatively high concentration of glutathione in cells (up to 5 mM in the liver). The regeneration of GSH
from GSSG is catalyzed by glutathione reductase (GR) in the GSH redox cycle. GSSG reduction occurs
at the expense of NADPH, produced by the pentose phosphate pathway (PPP) from glucose oxidation.
The intracellular GSH pool, present in millimolar concentrations, is involved in various GSH-dependent
reactions. Compartmentalization of GSH within the mitochondria, nucleus or endoplasmic reticulum
creates distinct and independently regulated subcellular redox pools.
Glutathione plays a cytoprotective role through several mechanisms. As a reducing agent, it is the
main cellular antioxidant agent in the reduction of hydrogen peroxide (H2O2) and lipid hydroperoxides
(LOOH) catalyzed by glutathione peroxidases (GPXs). In the reactions of protection against ROS,
the role of glutathione is illustrated by the reduction of peroxides:
2 GSH + R2O2→ GSSG + 2 ROH
R = H or alkyl group, and by the neutralization of free radicals:
GSH + R→ 0.5 GSSG + RH
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GSH takes part also in the reduction of protein disulfides (PrSSG) catalyzed by glutaredoxins
(GRXs). Moreover, it is employed in the preservation of protein-dithiols by the protein disulfide
reductase (glutathione) (EC 1.8.4.2), an enzyme that catalyzes the chemical reaction:
2 glutathione + protein disulfide↔ glutathione disulfide + protein-dithiol.
This enzyme acts on different substrates, such as insulin, which is inactivated by cleavage of the
disulfide bridge, or on protein disulfide, in which the reduction to protein-dithiol restores the catalytic
activity, protecting the cell from oxidant stress.
Another important function of glutathione is mediated by its conjugation to several substrates.
In the detoxifying defense systems, GSH participates in conjugation reactions catalyzed by
glutathione-S-transferases (GSTs). Many heavy metals such as mercury and lead are eliminated
as GSH conjugates to prevent their irreversible binding to SH groups of many enzymes, including
many membrane ATPase. Subacute exposure to lead results in GSH pool depletion and accumulation
of lipid peroxidation products and modifies the activity of the glutathione-related enzymes, such as
GR, GST and glucose-6-phosphate dehydrogenase [16]. Many lipophilic xenobiotics are conjugated to
GSH to facilitate their excretion or further metabolism. Conjugate compounds are exported from the
cell by GSH transporters, which requires ATP for active pumping [17]. In particular, the multidrug
resistance-associated proteins (MRP/ABCC) appear to mediate GSH export and homeostasis. The MRP
proteins mediate not only GSH efflux, but they also export oxidized glutathione derivatives (e.g.,
glutathione disulfide (GSSG), S-nitrosoglutathione (GS-NO) and glutathione-metal complexes), as well
as other glutathione S-conjugates [18]. Moreover, GSH can be conjugated to proteins in a process called
protein S-glutathionylation (PSSG). PSSG protects protein cysteines from being overoxidized to sulfinic
and sulfonic species that are not readily regenerated. S-glutathionylation also changes the protein
structure and function.
Due to the strong cytoprotective effects of GSH, alterations in GSH homeostasis have been
associated with neurodegenerative diseases, AIDS, liver and heart disease, aging, diabetes mellitus
and cancer (reviewed in [19–21]).
3. The Protective Actions of GSH
Glutathione can prevent damage to important cellular components caused by ROS and their
derivatives, such as free radicals, peroxides, lipid peroxides, or by organic pollutants and heavy metals.
In addition, due to the peculiar reactivity of the –SH group, GSH is involved in several chemical
reactions, from disulfide bridge reduction to conjugation to endogenous molecules and xenobiotics.
As the pool of the available GSH molecules is fixed, any unexpected increase of its utilization leads to a
decrease of the free molecules and impairment of the competing pathways. For example, when GSH is
conjugated, it is stolen from the enzymes using the molecule as a cofactor or substrate. This observation
is relevant to explain why a deficiency of GSH can occur and can affect pathways involved in severe
viral symptoms. Among the many functions of GSH, some are worthy of mention in relation to their
impact on the exacerbated inflammation taking place in COVID-19 and in relation to the symptoms
developed in the disease.
1. GSH protects cells by neutralizing (i.e., reducing) ROS, which are key signaling molecules that
play an important role in the progression of inflammatory disorders. The relationship between
ROS production and proinflammatory cytokine activation is well established [22]. An enhanced
ROS generation by polymorphonuclear neutrophils at the site of inflammation causes endothelial
dysfunction and tissue injury [23].
2. The conjugation of GSH to xenobiotics is particularly abundant; glutathione S-transferase
enzymes catalyze GSH conjugation to lipophilic xenobiotics, facilitating the excretion or further
metabolism of many drugs. The conjugation process is illustrated by the metabolism of
N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is a reactive metabolite formed by the action of
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cytochrome P450 on paracetamol (acetaminophen). Glutathione conjugates to NAPQI and the
resulting product is excreted [24].
3. Many enzymes use GSH as a cofactor or substrate. For example reactions requiring GSH as
a key cofactor are catalyzed by the prostaglandin H synthase, the rate-limiting enzyme in the
production of prostaglandins and thromboxane [25], which are essential regulators of vascular
function. Moreover, the enzyme leukotriene C(4) synthase conjugates LTA(4) with GSH to form
the leukotriene LTC(4), the parent compound of the cysteinyl leukotrienes [26]; these molecules
are potent mediators of airway narrowing.
4. GSH is used to synthesize S-nitrosoglutathione (GSNO), an endogenous S-nitrosothiol that plays
a critical role in nitric oxide (NO) signaling and is a source of bioavailable NO. The generation
of GSNO can serve as a stable NO pool which can properly transduce NO signaling [27].
NO produced by nitric oxide synthase eNOS and nNOS, in the presence of GSH, can effectively
modulate vessels and neuronal functions, regulating the blood flow according to the local
calcium influx.
As a consequence of the competition between these and many other GSH-consuming pathways,
on one hand, the raging inflammation and oxidative stress triggered by the viral infection steals GSH
from core functions such as NO-dependent vasodilatation; on the other hand, when other biochemical
pathways are consuming GSH, the patient is not protected from an inflammation that can prove fatal.
4. The Beneficial Effects of GSH on the Inflammation Driven by the Imbalance of ACE/ACE2
The harmful increase of ANGII can depend on many factors. First, it can be due to the increased
renin activity, which is not affected by GSH. Instead, ACE expression and activity are modulated
by glutathione; in fact, the oxidized form GSSG shows an activating effect on ACE activity, whereas
the reduced GSH provides an inhibitory effect [28]. Finally, the boosted ANGII production can be
due to decreased ACE2 expression and activity; this is the case with coronavirus infection, which
recognizes ACE2 as its extracellular binding site [29]. Compared to SARS-COV-1, SARS-CoV-2 has
about 4-fold higher affinity for ACE2 [30]. Infection of cells by SARS viruses that bind ACE2 results in
two effects: inhibition of ACE2 activity and decrease of ACE2 expression in infected cells [29,31,32].
The increased ANGII, through binding to AT1R, activates NADPH oxidases that transfer an electron
from NADPH to O2 generating several radical species, which can be scavenged by GSH. ROS-mediated
oxidation can, in turn, alter gene expression through the induction of signaling cascades or the
interaction with transcription factors [33]. Among these factors, a prominent role is played by NF-kB,
whose role in inflammation in severe acute respiratory syndrome (SARS) has been demonstrated in
both SARS-CoV-infected cultured cells and mice [34]. Drugs that inhibit NF-κB activation lead to a
reduction in inflammation and lung pathology. NF-kB is involved in inflammation through multiple
mechanisms. In vitro, the viral nucleocapsid (N) protein activates interleukin-6 (IL-6) expression
through NF-kB binding at the promoter region of the gene [35]. High levels of IL-6 in the acute stage
associated with lung lesions were found in SARS patients [36]. By reducing ROS production, GSH
inhibits NF-kB activation and consequently keeps the cytokine storm under control. The effects of
GSH are outlined in Figure 2.
The oxidant/antioxidant imbalance is not peculiar to SARS, but it is shared by all inflammatory
lung diseases in which the activation of redox-sensitive transcription factors such as NF-kB is reduced
by GSH [37]. In an animal model of oxidative stress, NF-κB binding activity was inversely related to
liver glutathione and was further suppressed by oral administration of green tea extract [38].
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Figure 2. The anti-inflammatory effects of reduced glutathione (GSH) are exerted through the inhibition
of ACE activity, decrease of reactive oxygen species (ROS) production and reduction of NF-kB activation
(red lines). The balance ACE/ACE2 is shifted toward ACE by the oxidized form of glutathione (GSSG)
and by renin (the circled arrows pointing upwards indicate the induction of ACE) and by viral infection
(the circled arrow pointing downwards indicates the downregulation of ACE2).
5. Conditions Associated with Low GSH
GSH plays a central role in the pathophysiology of human diseases (reviewed in [39]). GSH
imbalance is observed in a wide range of pathological conditions including lung infections, HIV,
diabetes, cancer and age-related diseases [20,40]. If we consider the conditions clinically associated
with severe COVID-19 disease [41–43], we find evidence of a perturbed GSH replenishment.
1. Age. Age is a major risk factor for both morbidity and mortality in COVID-19 patients [44,45].
In laboratory animals, the age-related changes in GSH content have been measured in different tissues.
Old mice had lower GSH than young mice in several organs. The sharp decrease in the lung is highly
remarkable because the sum of aging and air pollution can lead to very low GSH [46]. Similarly to the
data obtained in animals, several studies have reported that also in human subjects the concentration
of GSH declines with aging [47–52].
2. Sex. The severity of COVID-19 is strictly correlated to gender. While men and women
have the same prevalence of infection, men with COVID-19 are more at risk for worse outcomes
and death, independent of age. In the public data set, the number of men who have died from
COVID-19 is 2.4 times that of women (70.3 vs. 29.7%, p = 0.016) [53]. Several studies report decreased
GSH levels in men compared to women. Research investigating the effect of sex hormones on free
radicals and lipid peroxides production found that the erythrocyte glutathione level was lower in
healthy men than in healthy women and concluded that the decrease in GSH concentration was not
the result of reduced production but probably the result of more rapid utilization against increased
oxidative stress triggered by testosterone [54]. Another study reported that neonatal tissues show a
gender-dependent modulation of their glutathione metabolism; in fact, in response to oxidative stress,
endothelial cells as well as cells derived from tracheal aspirate of baby girls had a greater activity of
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glutathione reductase compared to tissues derived from baby boys [55]. A study aimed at determining
the influence of gender and antioxidant supplementation on exercise-induced oxidative stress reported
that, before supplementation, women had higher reduced glutathione and total glutathione compared
with men [56].
From data reported in the literature, the difference between sexes in GSH content can be related to
hormones or can be ascribed to significant sex-specific differences in drug-metabolizing enzymes.
Estrogens can downregulate the production of ROS triggered by the imbalance of the ACE/ACE2
system; therefore, women have a lower risk of GSH depletion. Indeed, ACE2 expression is modulated
by sex hormones. Estrogen modulates the local renin angiotensin system via downregulation of ACE
and simultaneous upregulation of ACE2, AT2R and ang (1-7) receptor expression levels [57]. Estradiol
directly activates ACE2 expression in different tissues, including differentiated airway epithelial
cells [57–59]. Moreover serum ACE is significantly lower in female children compared to males after
the age 12 [60]. 17beta-estradiol but not other sex hormones such as progesterone and testosterone
increases the content of GSH-dependent protein disulfide reductase and protects endothelial cells
from oxidative stress [61]. Estradiol production in the peripheral tissues is dependent on the local
availability of the precursor DHEA, produced from DHEA sulfate (DHEAS) by steroid-sulfatase.
Steroid-sulfatase becomes the limiting enzyme for the synthesis of estrogens in the elderly; whereas the
serum DHEAS in young males is much higher than in females, after menopause/andropause, it is very
similar. The overexpression of steroid-sulfatase in elderly women can lead to an estrogen production
higher than in men even after menopause.
Cortisol also seems to affect glutathione homeostasis. In fact, a study analyzing the administration
of anti-inflammatory glucocorticoids in cases of acute respiratory distress syndrome (ARDS) showed
that hydrocortisone administration was followed by glutathione depletion and lower glutathione
reductase activity in alveolar epithelial type II cells, thus failing to show beneficial effects [62]. Based
on these observations, it is possible to infer a role of cortisol in the gender difference of GSH level, as in
elderly women, urinary free cortisol excretion is lower than in the elderly men [63].
As for the different sex-related activities of metabolizing enzymes, the specific activity of the
catabolic enzyme gamma-glutamyltranspeptidase in female mice was 73% of that in male mice,
suggesting that the faster glutathione turnover in males could account for the higher susceptibility
to oxidative injury [64]. A time-dependent reduction of hepatic and renal cortical glutathione was
observed in both male and female mice following a dose of acetaminophen, but the depletion in male
mice was significantly greater than that in the females [65]. This means that even if in basal conditions
the GSH levels are similar, after challenges with drugs or pollutants requiring the GSH-dependent
detoxification system, the decrease of GSH is more evident in males than in females.
On a large sample of adults from North-Western Italy, vitamin D levels were found significantly
higher in women than in men, more elevated in summer than in winter and higher in individuals aged
less than 64 years compared to those older than 65 years [66]. As vitamin D induces the expression of
GCL and GR genes [14], thus increasing the levels of GSH, these small but significant differences must
also be taken into account as preventive factors of severe COVID-19.
3. Diabetes. The correlation between low GSH and diabetes is well established. Diabetes has
been widely associated with oxidative damage, increased GSSG/GSH ratio and decreased GSH content
in different tissues [67,68]. Decreased GSH is, in most cases, associated with increased activity of
NF-kB [69]. A study by Samiec and colleagues showed that the levels of total glutathione and its reduced
form were lower in plasma of older subjects and even lower in diabetic patients [70]. In diabetes,
the role of GSH as an antioxidant molecule is as critical as its contribution in maintaining the levels
of GSNO, the main donor of NO, as discussed above. Insulin resistance is negatively related to the
activity of endothelial NO synthase (eNOS), thus creating a link between metabolic and cardiovascular
diseases. Lower NO production induces both insulin resistance and hypertension [71]. The increase of
insulin sensitivity in muscle, adipocytes and liver depends more on GSNO than on pure NO [72,73].
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4. Hypertension. Diabetes and hypertension seem to be the most frequent comorbidities in dying
patients [74]. Hypertension may depend on multiple factors; among them it is relevant to cite the
activation of the renin-angiotensin system mainly by renin overexpression secondary to low vitamin D,
the decreased activity of eNOS and the decreased levels of GSH. As already described for diabetes,
the combination low GSH/low NO leads to a higher calcium influx into the vessel wall and in smooth
muscle with vasoconstriction, as demonstrated also in animal models [75]. Since in hypertensive
patients the low levels of GSH are often accompanied by a decrease of companion enzymes (catalase,
GSH-peroxidase and GST) and increased lipid peroxides, the prevailing hypothesis is that the GSH
decrease is due to a burst of ROS production, secondary to an inflammatory process [76]. It has been
demonstrated that GSH depletion induces chronic oxidative stress and causes hypertension in normal
rats. This is accompanied by inactivation and sequestration of NO by ROS, leading to diminished NO
bioavailability [77].
5. Obesity. Together with the most common comorbidities, hypertension (56.6%) and diabetes
(33.8%), obesity was also found to be closely associated with COVID-19 (41.7%) in patients hospitalized
in a US health care system [78]. Many studies suggest that in obese subjects oxidative stress and chronic
inflammation are important underlying factors leading to development of many pathologies such as
diabetes and cardiovascular diseases. Several studies have reported that in obese patients oxidative
stress is associated with diminished glutathione levels [79,80] and decreased GSH/GSSG ratio [81].
In addition, nutritional stress caused by a high fat high carbohydrate diet promotes oxidative stress,
as evident by increased lipid peroxidation products, a diminished antioxidant system and decreased
glutathione levels [82,83].
6. Pharmacotherapy. Glutathione S-transferase (GST) enzymes catalyze the conjugation of
GSH to lipophilic xenobiotics, which include most of the drugs. Acetaminophen (paracetamol) is
the best-known drug affecting GSH levels by this mechanism (more than 600 entries in PubMed
on this interaction). Many other drugs decrease GSH levels because they induce oxidative stress,
for example doxorubicin (adriamycin), antimalarial drugs, chloroquine (CQ), etoposide, opiates,
ethanol [84] and antidepressants [85]. The use of CQ deserves special caution because of its chemical
properties. In addition to its prooxidant activity leading to GSH depletion [86], chloroquine accumulates
into lysosomes leading to their alkalinization and to the impaired uptake of many nutrients from
the blood, including transferrin-bound iron. Iron deficiency in the nerve reduces cytochrome C
synthesis, respiratory chain activity and ATP synthesis. This toxicity is untreatable and can progress to
blindness [87].
Based on these observations, we conclude that many seemingly marginal health problems can
concur in creating an individual fragility in the antioxidant defenses, which could be aggravated by
the viral infection and could lead to the severe outcome of COVID-19.
6. Treatment with GSH and Thiols
Anti-oxidant therapies exert beneficial effects on many diseases characterized by inflammation
consequent to impaired redox homeostasis [88–90]. In the context of inflammatory diseases, systemic
oxidative stress is detected as decreased total free thiol levels (free sulfhydryl groups of cysteine in
proteins such as albumin as well as low-molecular-weight free thiols, for example cysteine, glutathione,
homocysteine and related species). A recent study has concluded that low molecular mass systemic
thiols might play a role in the inflammatory and oxidative stress pathways involved in both chronic
obstructive pulmonary disease (COPD) and cardiovascular disease [91]. The levels of systemic free
thiols can be influenced by nutritional or therapeutic intervention [92]. For these reasons, many clinical
trials have evaluated the efficacy of N-acetylcysteine (NAC) administration, and many are still ongoing
(714 studies, 349 completed), as well as the effects of GSH supplementation (162 studies, 100 completed)
(https://clinicaltrials.gov/).
NAC is both a thiol with antioxidant properties and one of the substrates in GSH biosynthesis.
The protective effects of the administration of antioxidant NAC on a murine asthma model was
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demonstrated in two studies. Treatment with NAC was able to attenuate the diminished ratio
GSH/GSSG in animals [93], and the repletion of glutathione pool by NAC counteracted allergen
induced airway reactivity/inflammation and restored oxidant-antioxidant balance [94].
In humans, NAC and GSH supplementation has demonstrated its efficacy in several pathologies,
and the most interesting results have been obtained in cardiovascular, pulmonary and viral diseases.
NAC has been found effective in acute myocardial infarction (AMI) [95]; indeed, oral NAC
supplementation reduced the levels of some inflammatory markers in AMI patients receiving fibrinolytic
therapy, and it was judged a therapeutic option for the successful management of these patients.
A study investigating the acute anti-hypertensive effect of anti-oxidant agents in hypertensive
subjects and diabetic patients found that the anti-oxidant GSH showed a significant hypotensive effect
probably due to the control exerted over the nitric oxide-free radical interaction [96].
In several chronic pulmonary diseases, the correlation between oxidative stress and pathogenesis
has been described. The levels of GSH were reported to be markedly decreased in lung fluids and
plasma of patients with idiopathic pulmonary fibrosis (IPF). Numerous studies have demonstrated
that the administration of various antioxidants is protective against the development of fibrosis in this
pathology; among them, some trials aimed at testing the efficacy of GSH precursor, NAC, reported
its efficacy in augmenting pulmonary GSH levels and alleviating oxidative stress, although with
different results (reviewed in [97]). Many studies found beneficial effects of NAC in COPD patients
(reviewed in [98]), although the efficacy of NAC in reducing disease severity was ascribed to NACs
mucolytic activity rather than its function as GSH precursor [97]. Alterations in GSH levels and in
some GSH-dependent enzymes have also been reported in asthma [97].
The levels of oxidative stress are also critical in the immune response to viruses. During viral
infections, an intracellular GSH depletion is mediated by multiple mechanisms and is crucial for viral
replication [99]. Although several in vitro and in vivo studies demonstrate that the administration
of GSH inhibits viral replication, to date very few clinical trials support the pharmacological use of
NAC in respiratory viral infection in vivo (reviewed in [100]). GSH treatment is a promising approach,
but high doses of GSH are necessary to achieve a therapeutic efficacy, due to its poor transport into the
cells and tissues. GSH delivery could be improved by some derivatives with hydrophobic chains of
different length or by I-152, which is a conjugate of NAC and s-acetyl-β-mercaptoethylamine (MEA),
which is able to release NAC and MEA and increase GSH content [100].
GSH has been used locally in the treatment of emphysema, where experimental pieces of evidence
demonstrated that the oxidative downregulation of the activity of α-1-proteinase inhibitor was curtailed
by glutathione, and the authors of the study suggest that this treatment can be considered an option for
acute respiratory crises due to COPD [101]. Previous clinical trials of nebulized GSH have demonstrated
the bioavailability and safety of up to 600 mg twice daily [101]. As an increased ROS production in
COVID-19 is the currently prevailing hypothesis, this approach could be suitable in this case as well.
GSH is one of the more represented molecules in our body: its concentration is 2–5 mM,
comparable to very abundant molecular species such as glucose in the blood (5 mM) and intracellular
ATP (5–10 mM). If we assume 40 kg of tissue with an average of 2.5 mM GSH (about 750 mg/L), it means
that there is 30 g of GSH in the whole body. With a half-life of 48 h, its life is around 10 days; this means
that tissue loses 3 g of GSH a day; therefore, the dietary support for full replacement is approximately
1.5 g glutamate, 0.75 g glycine and 1.20 g cysteine (1.63 g if assumed as N-acetyl-l-cysteine, NAC) a
day. Body GSH concentration may be increased with oral intake of either GSH, or proteins enriched in
the amino acid constituents of GSH, or the supplementation of the two limiting amino acids cysteine
and glycine, as the body availability of glutamate is usually not limiting. Oral administration of
GSH is more expensive than supplements with cysteine and glycine, and its systemic bioavailability
may be poor due to degradation in the gut; therefore, its suitability for use on a large population
could be limited. Interestingly, a case report study has shown that the repeated use of both 2000 mg
of oral administration and intravenous injection of glutathione was effective in relieving the severe
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respiratory symptoms of COVID-19, showing for the first time the efficacy of this antioxidant therapy
for COVID-19 [102].
Dietary supplementation with the glutathione precursors cysteine and glycine, in proper conditions,
fully restores glutathione synthesis and concentrations. Some observations support this practical
and effective approach to decrease oxidative stress in aging and diseases associated with low GSH
concentration [103]. It was demonstrated that elderly subjects had markedly lower red blood cell
concentrations of GSH (53%) compared with younger controls. After oral treatment of 14 days with
0.81 mmol cysteine (132 mg NAC)·kg−1·d−1 and 1.33 mmol glycine (100 mg)·kg−1·d−1, the elderly
reached the GSH concentration of the younger controls [103].
Five clinical trials are at the moment evaluating the effects of supplementation with N-acetylcysteine
plus glycine (https://clinicaltrials.gov/).
NAC has been largely used in the past as a treatment for bronchitis. A meta-analysis evaluating
13 studies and a total of 4155 people with COPD concluded that the standard dose of 1200 milligrams of
N-acetylcysteine per day reduces the incidence and severity of flares (known as exacerbations) compared
to a placebo [104]. Considering NAC as one of the substrates in GSH biosynthesis, the stoichiometric
dose of glycine should be about 1000 mg (exactly 938 mg). This amount roughly corresponds to
the daily turnover in healthy people and seems a reasonable dosage free of side effects, either for a
preventive or therapeutic approach.
7. Conclusions
The outlined overview describes how SARS-CoV-2 can unbalance a high activity of the
renin-angiotensin system in the lung via ACE2 downregulation, followed by free radical mediated
inflammation, and unveils the protective role of GSH; this biochemical approach to COVID-19
disease opens novel avenues for further investigation aimed at understanding the involved
molecular mechanisms.
Several pieces of evidence reported in our biochemical analysis suggest that low levels of GSH
could be one of the major causes of the excessive inflammatory response linked to severe COVID-19
symptoms and indicate that increasing body GSH could reduce the number of symptomatic patients.
Future clinical studies investigating the levels of GSH in COVID-19 patients may be the starting point
to explore this possibility.
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